Varenicline Tartrate Kit
Product Images NDC 68462-895

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Varenicline Tartrate (NDC 68462-895). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (89b8956b Cf71 4791 8e55 598ff52656f3 01)

Chemical structure diagram of varenicline tartrate showing its molecular framework including the tartrate moiety and varenicline bicyclic rings with nitrogen atoms.*

FDA Label Image

Figure1 (89b8956b Cf71 4791 8e55 598ff52656f3 02)

Bar chart titled 'Continuous Abstinence, Weeks 9 through 12' showing percentage abstinence rates across five studies comparing varenicline tartrate tablets at different dosages, bupropion SR 150 mg BID, and placebo. Each study group has bars with error bars indicating variability, highlighting comparative abstinence outcomes among the treatments.*

FDA Label Image

Logo (89b8956b Cf71 4791 8e55 598ff52656f3 03)

FDA Label Image

Dis (89b8956b Cf71 4791 8e55 598ff52656f3 04)

FDA Label Image

Starter Carton Pack (89b8956b Cf71 4791 8e55 598ff52656f3 05)

Packaging label for Varenicline Tablets by Glenmark Pharmaceuticals Inc., USA. The label shows a starting month box containing 0.5 mg and 1 mg film-coated tablets of varenicline tartrate in oral tablet form. It includes dispensing instructions, storage conditions, dosage guidance, medication guide availability, and contact information for the manufacturer. The label indicates the product is Rx only, made in India, with barcode and lot control details.*

FDA Label Image

Starter Wallet Pack (89b8956b Cf71 4791 8e55 598ff52656f3 06)

Packaging label for Varenicline Tablets by Glenmark Pharmaceuticals Inc., USA, showing a starting pack with blister cards for oral film-coated tablets. The label details dosing weeks with 0.5 mg and 1 mg tablets, and includes instructions to dispense the medication guide separately. The pack is labeled Rx only.*

FDA Label Image

0.5 mg 56 Bottles (89b8956b Cf71 4791 8e55 598ff52656f3 07)

Label for Varenicline Tablets 0.5 mg film-coated tablets by Glenmark Pharmaceuticals Inc., USA. The label indicates 56 tablets in the package, prescription only, with storage instructions at 20° to 25°C. It includes dispensing and medication guide information, plus a barcode and distribution details.*

FDA Label Image

1 mg- 56 Bottles Pack (89b8956b Cf71 4791 8e55 598ff52656f3 08)

Label for Varenicline Tablets 1 mg, film-coated oral tablets distributed by Glenmark Pharmaceuticals Inc., USA. The package contains 56 tablets and includes storage instructions, a medication guide URL, and a barcode. The label specifies the tablets provide 1 mg varenicline free base equivalent and include warnings about child-resistant packaging and storage conditions.*

FDA Label Image

Continuing Wallet Pack (89b8956b Cf71 4791 8e55 598ff52656f3 09)

Varenicline Tablets continuing pack carton from Glenmark Pharmaceuticals Inc., USA. The label indicates 4 continuing weeks of 1 mg tablets, 56 tablets total. The packaging shows multiple blister packs labeled by day and morning/evening doses for 28 days each, arranged side by side. The carton includes the NDC 68462-894-04 and states Rx only.*

FDA Label Image

Continuing Carton Pack (89b8956b Cf71 4791 8e55 598ff52656f3 10)

Packaging label for Varenicline Tablets, 1 mg, film-coated oral tablets by Glenmark Pharmaceuticals Inc., USA. The label identifies the product as a continuing month box containing 56 tablets (4 weeks of 1 mg tablets). It includes dosage instructions, storage conditions, manufacturer information, and barcodes on a blue and white folded carton.*

FDA Label Image

Image (89b8956b Cf71 4791 8e55 598ff52656f3 188 1)

A vertical bar chart titled 'Figure 2: Continuous Abstinence, Weeks 9 through 52' compares the percentage of continuous abstinence across five studies. The x-axis lists treatments including varenicline tablets (0.5 mg BID and 1.0 mg BID), bupropion SR (150 mg BID), and placebo groups. The y-axis shows abstinence rates from 0% to 35%, with bars representing mean values and error bars indicating variability.*

FDA Label Image

Image (89b8956b Cf71 4791 8e55 598ff52656f3 192 1)

A line graph showing continuous abstinence rates during nontreatment follow-up over a 52-week period. The graph compares varenicline tablets 1.0 mg BID with placebo, with percent continuous abstinent on the y-axis and nontreatment follow-up in weeks on the x-axis. Varenicline demonstrates higher abstinence rates than placebo throughout the follow-up period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.